TIDMHEMO
RNS Number : 5280J
Hemogenyx Pharmaceuticals PLC
03 April 2018
Hemogenyx Pharmaceuticals Plc
("Hemogenyx" or the "Company")
Directorate Change
Professor Sir Marc Feldmann, pioneer of anti-TNF therapy,
appointed as Executive Chairman
Anti-TNF therapy is the world's largest drug class with more
than US $36bn in sales
Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology
company developing novel therapies to transform bone marrow, or
blood stem cell, transplantation for the treatment of blood
diseases, announces the appointment of Sir Marc Feldmann, AC, FRS,
as Executive Chairman effective as of 9 April 2018. He has a unique
blend of scientific, medical and commercial experience and
expertise.
Sir Marc shares the Academic credit for inventing and developing
anti-TNF therapy for rheumatoid arthritis, the first major use of
monoclonal antibodies in a common disease. Centocor, Inc licensed
Sir Marc's key patent, and then developed Infliximab, ultimately
branded as Remicade. Remicade was the main driver of the $4.9
billion acquisition of Centocor by Johnson and Johnson in 1999, and
is still J&J's best selling drug. Since 2012 Anti-TNF therapy
has become the world's largest drug class with sales in 2016
exceeding US$36 billion. Sir Marc was previously Chairman of the
Company's Scientific Advisory Board and has a remarkably broad
experience of discovering new medicines, having worked through all
stages from developing new concepts of how diseases emerge, through
testing ideas and early clinical development, leading clinical
trials, approval, registration and commercial reality.
Robin Campbell, Chairman, will become a Non-Executive Director
and Adrian Beeston, Non-Executive Director, will step down from the
Board, both with immediate effect.
About Sir Marc Feldmann
Professor Sir Marc Feldmann is a pre-eminent medically trained
immunologist at the University of Oxford where he was Head of the
Kennedy Institute of Rheumatology until 2014 and now Emeritus
Professor. He trained in medicine at Melbourne University and then
earned a Ph.D. in Immunology at the Walter & Eliza Hall
Institute with Sir Gus Nossal, before working in London at the
Imperial Cancer Research Fund. Sir Feldmann's main research
interests are immunoregulation, understanding mechanisms of
autoimmunity and the role of cytokines in disease, and working out
how to fill unmet medical needs.
His work in London led to the generation of a new hypothesis for
the mechanism of autoimmunity, linking upregulated antigen
presentation and cytokine expression. Testing this hypothesis led
to the discovery, with colleague Sir Ravinder Maini, of the pivotal
role of TNF<ALPHA> (Tumor Necrosis Factor alpha) in the
pathogenesis of rheumatoid arthritis. This major discovery has
revolutionised therapy not only of rheumatoid arthritis but other
chronic inflammatory diseases (eg Inflammatory bowel disease,
psoriasis, ankylosing spondylitis), and helped change the
perception of monoclonal antibodies from niche products to
mainstream therapeutics. Anti-TNF therapeutics are the current
leading drug class with 2016 sales exceeding US $36 Billion.
This has led to much scientific recognition, for example
election to the Royal Society and Academy of Medical Sciences in
London, the National Academy of Sciences USA and the Australian
Academy of Science, and multiple major International prizes:
including the Crafoord Prize of the Royal Swedish Academy of
Sciences, the Albert Lasker Clinical Research Award (NY), the Ernst
Schering Prize , the Paul Janssen Award for Biomedical Research and
the Canada-Gairdner Award. He was also the first recipient in
biology or medicine of the EU/ European Patent office Inventor of
the Year Award in the Lifetime Achievement category. In addition,
Sir Marc has advised more than 20 of the largest pharmaceutical and
biotech companies in the world and has mentored some of the most
successful scientists, many of whom have become senior figures in
the commercial pharmaceutical world. Sir Marc was knighted in the
2010 Queen's Birthday Honours, and was honoured in Australia with
the knighthood equivalent, the Companion of the Order of
Australia.
Sir Marc has elected to receive most of his remuneration for his
role as Chairman and as Chairman of the Scientific Advisory Board
in shares in the Company.
Dr. Vladislav Sandler, CEO of Hemogenyx, commented:
"I am delighted that after eight months as Chairman of our
Scientific Advisory Board, Sir Marc has agreed to join us as
Chairman. I know that Sir Marc shares our enthusiasm for developing
transformational therapies for Bone Marrow and Blood Stem Cell
transplants that will have a major impact on the way we routinely
treat lethal blood diseases. Since Sir Marc has been at the
forefront of promoting effective scientific-medical-pharmaceutical
interactions, he has built up a huge network of friends and
collaborators who meet regularly in Oxford and they will help
Hemogenyx grow and go clinical.
"I would also like to extend my thanks to Robin for his role as
Chairman and his continued contribution as a Non-Executive Director
and we also thank Adrian for his support on the Board and we wish
him well."
Sir Marc Feldmann, said:
"I am pleased to become Chairman of Hemogenyx. There is a huge
unmet need for more effective transplantation, and while bone
marrow transplants are the most frequently performed, there are
still problems to solve to improve their efficacy. Vladik Sandler's
pioneering work has led to a strategy for improving clinical BM
transplantation that I will together with members of my network
help Hemogenyx to deliver."
Enquiries:
Hemogenyx Pharmaceuticals Limited www.hemogenyx.com
Dr Vladislav Sandler, Chief Via Walbrook PR
Executive Officer & Co-Founder
Sir Marc Feldmann, Chairman
Optiva Securities Ltd Tel: +44 (0)20 3137 1902
Christian Dennis
Shard Capital Partners LLP Tel: +44 (0)20 7186 9950
Damon Heath, Erik Woolgar
Peterhouse Corporate Finance Tel: +44 (0)20 7469 0930
Limited
Lucy Williams/Duncan Vasey
Walbrook PR (UK Media & Tel: +44 (0)20 7933 8780 or
Investor Relations) hemogenyx@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
US Media enquiries
Lowell Goodman Tel: +1 (323) 646-3249 or lowell@lowellgoodman.net
About Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE:
HEMO) headquartered in London, with its wholly owned U.S. operating
subsidiary, HemoGenyx LLC, located in its state-of-the-art research
facility in Brooklyn, New York.
HemoGenyx is a preclinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of
novel therapies and treatments for blood diseases such as leukemia
and lymphoma. The company's leading technologies aim to change the
way in which bone marrow/hematopoietic stem cell (BM/HSC)
transplants are performed and improve their efficacy. HemoGenyx's
two distinct and complementary products include an immunotherapy
product for patient conditioning-the CDX bi-specific antibody-and a
cell therapy product for BM/HSC transplantation-the HuPHEC. Each of
these products holds the potential to revolutionize the way BM/HSC
transplants are being performed, offering solutions that mitigate
the dangers and limitations associated with the current standard of
care.
For more information, visit www.hemogenyx.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAUGUPACUPRGPP
(END) Dow Jones Newswires
April 03, 2018 02:01 ET (06:01 GMT)
Hemogenyx Pharmaceuticals (LSE:HEMO)
過去 株価チャート
から 6 2024 まで 7 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
過去 株価チャート
から 7 2023 まで 7 2024